381 related articles for article (PubMed ID: 25646413)
1. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
[TBL] [Abstract][Full Text] [Related]
2. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
[TBL] [Abstract][Full Text] [Related]
3. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
[TBL] [Abstract][Full Text] [Related]
4. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
5. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
6. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.
Liu J; Chen G; Feng L; Zhang W; Pelicano H; Wang F; Ogasawara MA; Lu W; Amin HM; Croce CM; Keating MJ; Huang P
Leukemia; 2014 Jan; 28(1):118-28. PubMed ID: 23608884
[TBL] [Abstract][Full Text] [Related]
7. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
9. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
10. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
11. Is miR-29 an oncogene or tumor suppressor in CLL?
Pekarsky Y; Croce CM
Oncotarget; 2010 Jul; 1(3):224-7. PubMed ID: 20936047
[TBL] [Abstract][Full Text] [Related]
12. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
[TBL] [Abstract][Full Text] [Related]
13. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
14. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia?
Cardinaud B; Moreilhon C; Marcet B; Robbe-Sermesant K; LeBrigand K; Mari B; Eclache V; Cymbalista F; Raynaud S; Barbry P
Leukemia; 2009 Nov; 23(11):2174-7. PubMed ID: 19536169
[No Abstract] [Full Text] [Related]
15. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
[TBL] [Abstract][Full Text] [Related]
16. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia.
Calin GA; Pekarsky Y; Croce CM
Best Pract Res Clin Haematol; 2007 Sep; 20(3):425-37. PubMed ID: 17707831
[TBL] [Abstract][Full Text] [Related]
17. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
[TBL] [Abstract][Full Text] [Related]
18. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
19. miR deregulation in CLL.
Balatti V; Pekarky Y; Rizzotto L; Croce CM
Adv Exp Med Biol; 2013; 792():309-25. PubMed ID: 24014303
[TBL] [Abstract][Full Text] [Related]
20. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
Prinz C; Vasyutina E; Lohmann G; Schrader A; Romanski S; Hirschhäuser C; Mayer P; Frias C; Herling CD; Hallek M; Schmalz HG; Prokop A; Mougiakakos D; Herling M
Mol Cancer; 2015 Jun; 14():114. PubMed ID: 26041471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
